WO2002002751A3 - Alteration of cell membrane - Google Patents
Alteration of cell membrane Download PDFInfo
- Publication number
- WO2002002751A3 WO2002002751A3 PCT/US2001/020946 US0120946W WO0202751A3 WO 2002002751 A3 WO2002002751 A3 WO 2002002751A3 US 0120946 W US0120946 W US 0120946W WO 0202751 A3 WO0202751 A3 WO 0202751A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alteration
- cell membrane
- regulation
- proteins
- sequences
- Prior art date
Links
- 210000000170 cell membrane Anatomy 0.000 title abstract 2
- 230000004075 alteration Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108091029865 Exogenous DNA Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000003828 downregulation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000003827 upregulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
- Y10S530/816—Attached to the carrier via a bridging agent
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01984107A EP1299522B1 (en) | 2000-06-30 | 2001-07-02 | Alteration of cell membrane |
AT01984107T ATE531789T1 (en) | 2000-06-30 | 2001-07-02 | CELL MEMBRANE CHANGES |
JP2002507992A JP2004524806A (en) | 2000-06-30 | 2001-07-02 | Changing cell membranes for new functions |
AU2002216763A AU2002216763B2 (en) | 2000-06-30 | 2001-07-02 | Alteration of cell membrane |
CA2413237A CA2413237C (en) | 2000-06-30 | 2001-07-02 | Alteration of cell membrane for new functions |
AU1676302A AU1676302A (en) | 2000-06-30 | 2001-07-02 | Alteration of cell membrane for new functions |
US10/312,245 US7238360B2 (en) | 2000-06-30 | 2001-07-02 | Alteration of cell membrane with B7 |
US11/819,080 US8076096B2 (en) | 2000-06-30 | 2007-06-25 | Alteration of cell membrane with FasL |
US13/316,915 US8728747B2 (en) | 2000-06-30 | 2011-12-12 | Alteration of cell membrane for new functions |
US14/280,940 US9255133B2 (en) | 2000-06-30 | 2014-05-19 | Alteration of cell membrane for new functions using IL-2 and streptavidin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21558000P | 2000-06-30 | 2000-06-30 | |
US60/215,580 | 2000-06-30 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/312,245 A-371-Of-International US7238360B2 (en) | 2000-06-30 | 2001-07-02 | Alteration of cell membrane with B7 |
US10312245 A-371-Of-International | 2001-07-02 | ||
US11/819,080 Continuation US8076096B2 (en) | 2000-06-30 | 2007-06-25 | Alteration of cell membrane with FasL |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002002751A2 WO2002002751A2 (en) | 2002-01-10 |
WO2002002751A3 true WO2002002751A3 (en) | 2002-10-03 |
Family
ID=22803538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/020946 WO2002002751A2 (en) | 2000-06-30 | 2001-07-02 | Alteration of cell membrane |
Country Status (7)
Country | Link |
---|---|
US (4) | US7238360B2 (en) |
EP (1) | EP1299522B1 (en) |
JP (1) | JP2004524806A (en) |
AT (1) | ATE531789T1 (en) |
AU (2) | AU1676302A (en) |
CA (1) | CA2413237C (en) |
WO (1) | WO2002002751A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7927602B2 (en) * | 2002-07-23 | 2011-04-19 | University Of Louisville Research Foundation, Inc. | Fas ligand-avidin/streptavidin fusion proteins |
JP2004524806A (en) | 2000-06-30 | 2004-08-19 | ユニバーシティ オブ ルイビル リサーチ ファウンデーション,インコーポレイティド | Changing cell membranes for new functions |
US9321992B2 (en) | 2002-06-14 | 2016-04-26 | Case Western Reserve University | Cell targeting methods and compositions |
US7373559B2 (en) * | 2003-09-11 | 2008-05-13 | Copan Systems, Inc. | Method and system for proactive drive replacement for high availability storage systems |
NZ562946A (en) * | 2005-04-29 | 2011-08-26 | Univ Louisville Res Found | Cell-surface decoration with active agents |
EP3130350A1 (en) * | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
EP1973573B1 (en) * | 2005-12-08 | 2013-05-22 | University of Louisville Research Foundation, Inc. | Methods and compositions for expanding t regulatory cells |
WO2007067681A2 (en) * | 2005-12-08 | 2007-06-14 | University Of Louisville Research Foundation, Inc. | Immunostimulatory compositions and methods |
CA2648030C (en) * | 2006-03-27 | 2018-02-13 | Children's Hospital & Regional Medical Center | Compositions and methods comprising the use of cell surface displayed homing endonucleases |
HUE030139T2 (en) * | 2006-12-27 | 2017-04-28 | Univ Emory | Compositions and methods for the treatment of infections |
JP5520961B2 (en) * | 2008-11-28 | 2014-06-11 | エモリー ユニバーシティ | Methods for treating infections and tumors |
WO2012011113A2 (en) * | 2010-07-22 | 2012-01-26 | Shai Yarkoni | Regulatory immune cells with enhanced targeted cell death effect |
WO2016205714A1 (en) * | 2015-06-19 | 2016-12-22 | University Of Louisville Research Foundation, Inc. | Immunomodulation for the long term prevention and treatment of autoimmune diseases and foreign tissue rejection |
US10906951B2 (en) | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
EP3828266B1 (en) | 2015-07-29 | 2022-11-23 | ONK Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
WO2018165547A1 (en) | 2017-03-10 | 2018-09-13 | University Of Louisville Research Foundation, Inc. | Fasl-engineered biomaterials with immunomodulatory function |
EP3798305A4 (en) | 2018-04-27 | 2022-02-09 | Aimed Bio Inc. | Magnetic-based biopanning method through attachment of magnetic bead to cell |
US11504335B2 (en) | 2018-06-18 | 2022-11-22 | University Of Kentucky Research Foundation | Increased cell retention in diseased site when cells encapsulated in gelatin methacrylate and polyethylene glycol diacrylate hydrogels |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999017801A2 (en) * | 1997-10-03 | 1999-04-15 | Cancer Research Campaign Technology Limited | Materials and methods relating to the stimulation of cells |
WO2001052664A1 (en) * | 2000-01-24 | 2001-07-26 | University Of Louisville Research Foundation, Inc. | Immune modulation with death receptor-induced apoptosis |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991001004A1 (en) * | 1989-07-06 | 1991-01-24 | Seragen, Inc. | Hybrid molecules |
US6071716A (en) * | 1990-10-01 | 2000-06-06 | Dana-Farber Cancer Institute | DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells |
US5470701A (en) * | 1993-02-24 | 1995-11-28 | The Regents Of The University Of California | Method for determining favorable prognosis in an HIV positive subject using HLA-DR+ /CD38- CD8bright cells |
US6130316A (en) * | 1993-07-26 | 2000-10-10 | Dana Farber Cancer Institute | Fusion proteins of novel CTLA4/CD28 ligands and uses therefore |
US5858776A (en) * | 1993-11-03 | 1999-01-12 | Repligen Corporation | Tumor cells with increased immunogenicity and uses therefor |
US6218510B1 (en) * | 1994-03-02 | 2001-04-17 | Brigham & Woman's Hospital | B7-1 and B7-2 polypeptides |
JP4435304B2 (en) * | 1995-06-29 | 2010-03-17 | イミュネックス・コーポレーション | Cytokines that induce apoptosis |
CA2230852A1 (en) * | 1995-08-30 | 1997-03-06 | The Regents Of The University Of California | Therapy for cellular accumulation in chronic inflammatory diseases |
GB9523469D0 (en) | 1995-11-16 | 1996-01-17 | Sandoz Ltd | Organic compounds |
WO1997033617A1 (en) | 1996-03-13 | 1997-09-18 | Protein Design Labs, Inc. | Fas ligand fusion proteins and their uses |
US6060054A (en) | 1996-04-10 | 2000-05-09 | National Jewish Medical And Research Center | Product for T lymphocyte immunosuppression |
US6042826A (en) * | 1996-11-15 | 2000-03-28 | Health Research, Inc. | Method for inducing apoptosis of primary central nervous system B cell lymphomas |
US7144991B2 (en) | 1999-06-07 | 2006-12-05 | Aletheon Pharmaceuticals, Inc. | Streptavidin expressed gene fusions and methods of use thereof |
JP2003517311A (en) | 1999-12-16 | 2003-05-27 | ユニバーシティ オブ ルイビル リサーチ ファウンデーション,インコーポレイティド | Compositions and methods for caspase-induced apoptosis |
US7927602B2 (en) | 2002-07-23 | 2011-04-19 | University Of Louisville Research Foundation, Inc. | Fas ligand-avidin/streptavidin fusion proteins |
JP2004524806A (en) | 2000-06-30 | 2004-08-19 | ユニバーシティ オブ ルイビル リサーチ ファウンデーション,インコーポレイティド | Changing cell membranes for new functions |
WO2007067681A2 (en) | 2005-12-08 | 2007-06-14 | University Of Louisville Research Foundation, Inc. | Immunostimulatory compositions and methods |
EP1973573B1 (en) | 2005-12-08 | 2013-05-22 | University of Louisville Research Foundation, Inc. | Methods and compositions for expanding t regulatory cells |
-
2001
- 2001-07-02 JP JP2002507992A patent/JP2004524806A/en active Pending
- 2001-07-02 EP EP01984107A patent/EP1299522B1/en not_active Expired - Lifetime
- 2001-07-02 CA CA2413237A patent/CA2413237C/en not_active Expired - Fee Related
- 2001-07-02 US US10/312,245 patent/US7238360B2/en not_active Expired - Lifetime
- 2001-07-02 AU AU1676302A patent/AU1676302A/en active Pending
- 2001-07-02 WO PCT/US2001/020946 patent/WO2002002751A2/en active IP Right Grant
- 2001-07-02 AT AT01984107T patent/ATE531789T1/en active
- 2001-07-02 AU AU2002216763A patent/AU2002216763B2/en not_active Ceased
-
2007
- 2007-06-25 US US11/819,080 patent/US8076096B2/en not_active Expired - Fee Related
-
2011
- 2011-12-12 US US13/316,915 patent/US8728747B2/en not_active Expired - Fee Related
-
2014
- 2014-05-19 US US14/280,940 patent/US9255133B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999017801A2 (en) * | 1997-10-03 | 1999-04-15 | Cancer Research Campaign Technology Limited | Materials and methods relating to the stimulation of cells |
WO2001052664A1 (en) * | 2000-01-24 | 2001-07-26 | University Of Louisville Research Foundation, Inc. | Immune modulation with death receptor-induced apoptosis |
Non-Patent Citations (3)
Title |
---|
CHEN A ET AL: "Hierarchical costimulator thresholds for distinct immune responses: application of a novel two-step Fc fusion protein transfer method.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 15 JAN 2000, vol. 164, no. 2, 15 January 2000 (2000-01-15), pages 705 - 711, XP002202890, ISSN: 0022-1767 * |
DARLING D ET AL: "In vitro immune modulation by antibodies coupled to tumour cells", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 4, no. 12, 1 December 1997 (1997-12-01), pages 1350 - 1360, XP002097146, ISSN: 0969-7128 * |
SANO T ET AL: "A STREPTAVIDIN-METALLOTHIONEIN CHIMERA THAT ALLOWS SPECIFIC LABELING OF BIOLOGICAL MATERIALS WITH MANY DIFFERENT HEAVY METAL IONS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 89, March 1992 (1992-03-01), pages 1534 - 1538, XP002938748, ISSN: 0027-8424 * |
Also Published As
Publication number | Publication date |
---|---|
US20120213730A1 (en) | 2012-08-23 |
US8728747B2 (en) | 2014-05-20 |
US20150086506A1 (en) | 2015-03-26 |
US20030219419A1 (en) | 2003-11-27 |
ATE531789T1 (en) | 2011-11-15 |
US8076096B2 (en) | 2011-12-13 |
US20090074870A1 (en) | 2009-03-19 |
CA2413237A1 (en) | 2002-01-10 |
EP1299522B1 (en) | 2011-11-02 |
WO2002002751A2 (en) | 2002-01-10 |
US7238360B2 (en) | 2007-07-03 |
AU1676302A (en) | 2002-01-14 |
JP2004524806A (en) | 2004-08-19 |
CA2413237C (en) | 2013-09-10 |
US9255133B2 (en) | 2016-02-09 |
AU2002216763B2 (en) | 2007-03-01 |
EP1299522A2 (en) | 2003-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002002751A3 (en) | Alteration of cell membrane | |
WO2000066753A3 (en) | Modified vitamin k-dependent polypeptides | |
WO2001075087A3 (en) | Subtilisin variants | |
WO1998021343A8 (en) | Genes encoding telomerase proteins | |
WO2001011011A3 (en) | Multipotent adult stem cells and methods for isolation | |
DK1210411T3 (en) | Compositions and Methods for Improved Cell Culture | |
WO2002006457A3 (en) | Novel lipase genes | |
WO2000058488A3 (en) | Delivery of functional protein sequences by translocating polypeptides | |
MXPA03001930A (en) | Tnf receptor-like molecules and uses thereof. | |
WO2000056866A3 (en) | Akt-3 nucleic acids, polypeptides, and uses thereof | |
WO2003020892A3 (en) | Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY | |
CA2336261A1 (en) | Cyclin e2 genes and proteins | |
WO2000029551A3 (en) | Cells, culture methods, and their use in autologous transplantation therapy | |
WO2001049721A3 (en) | Bacterial genes and proteins that are essential for cell viability and their uses | |
CA2278808A1 (en) | Methods for cultivating cells and propagating viruses | |
PT1140023E (en) | INTEGRATING COCLEAR FORMULATIONS OF PROTEIN-DNA AND METHODS OF CELLULAR TRANSFORMATION | |
WO1998055507A3 (en) | Modulators of intracellular inflammation, cell death and cell survival pathways containing a card and kinase domain | |
PT1062336E (en) | TNF / NGF RECEPTOR FAMILY RECEIVERS FUNCTION MODULATORS AND OTHER PROTEINS | |
WO2003070878A3 (en) | Antisense modulation of hematopoietic cell protein tyrosine kinase expression | |
WO2000024771A3 (en) | Nucleic acids encoding osteoprotegerin-like proteins and methods of using same | |
WO2001064912A3 (en) | Triazine degrading enzymes | |
AU2275697A (en) | Use of cell membrane permeants in the treatment of cellular proliferative disea ses | |
WO2002014369A3 (en) | Human kininogen d5 domain polypeptides and their use | |
WO2001000854A3 (en) | Chimeric proteins mediating targeted apoptosis | |
WO2002048187A3 (en) | Secretion signal peptides, their dna sequences, expression vectors for eukaryotic cells that can be produced with the same, and use thereof for biotechnological production of proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2413237 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002216763 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001984107 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001984107 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10312245 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002216763 Country of ref document: AU |